Estimates of baseline trend, level and trend changes, absolute and relative changes in utilisation, clinical outcomes and healthcare costs per patient following the E2 access program
| At 1 year after E2 implementation | At 2 years after E2 implementation | ||||||
|---|---|---|---|---|---|---|---|
| Impact of policy | Quarterly baseline trend prepolicy (95% CI) | Level change postpolicy (95% CI) | Quarterly trend change postpolicy (95% CI) | Absolute change (95% CI) | Relative change (95% CI) | Absolute change (95% CI) | Relative change (95% CI) |
| All patients | |||||||
| Utilisation | 0.1% (−0.4% to 0.6%) | 9.8% (6.8% to 12.8%) | −0.2% (−0.7% to 0.3%) | 8.7% (3.5% to 13.9%) | 12.7% (4.4% to 21.0%) | 8.0% (1.0% to 14.9%) | 11.5% (0.3% to 22.7%) |
| Outcomes | 0.05% (−0.4% to 0.5%) | 5.4% (2.0% to 8.7%) | −0.06% (−0.6% to 0.5%) | 5.0% (−1.1% to 11.1%) | 6.6% (−1.9% to 15.1%) | 4.8% (−3.3% to 12.8%) | 6.2% (−5.0% to 17.5%) |
| Costs | $56.39 (−$61.96 to $174.73) | −$687.10 (−$1534.65 to $160.44) | −$94.42 (−$220.76 to $31.91) | −$1253.66 (−$4756.70 to $176.85) | −13.5% (−26.9% to −0.2%) | −$1631.37 (−$3520.85 to $258.66) | −17.2% (−33.7% to −0.7%) |
| UC patients | |||||||
| Utilisation | −0.4% (−0.1% to 0.9%) | 14.5% (11.8% to 17.2%) | −0.3% (−0.9% to 0.2%) | 12.4% (6.8% to 18.0%) | 19.6% (9.1% to 30.3%) | 11.0% (3.3% to 18.7%) | 17.0% (3.1% to 31.0%) |
| Outcomes | −0.1% (−1.5% to 1.3%) | 8.7% (0.3% to 17.0%) | 0.07% (−1.4% to 1.5%) | 9.07% (−7.4% to 25.5%) | 12.5% (−13.0% to 37.9%) | 9.3% (−12.8% to 31.5%) | 12.9% (−21.7% to 47.6%) |
| Costs | $165.05 ($27.35 to $302.76) | −$1593.10 (−$2699.70 to −$486.51) | −$217.26 (−$356.20 to −$78.32) | −$2896.69 (−$4756.70 to −$1036.68) | −27.9% (−40.9% to −15.0%) | −$3765.75 (−$6157.79 to −$1373.71) | −34.2% (−48.5% to −19.8%) |
$, US$ in year 2014,15 adjusted by Consumer Price Index16.
UC, universal coverage.